Aditxt (ADTX) Company Report

Aditxt has filed a preliminary proxy statement seeking shareholder approval for an Employee Stock Purchase Plan and a non-binding advisory vote on an amendment to change its name from "Aditxt, Inc." to "bitXbio, Inc.".
The company is implementing its bitXbio™ strategy, a framework designed to connect public markets, blockchain, Web3, and digital asset treasuries for advancing health innovations. As part of this, a Digital Asset Treasury (DAT) is planned, though Aditxt currently holds no digital assets as of November 18, 2025.
Aditxt's precision diagnostics subsidiary, Pearsanta, has announced a planned initial public offering (IPO) in 2026, subject to market conditions, to commercialize its Mitomic® and Adductomics testing platforms.
Evofem, in which Aditxt holds significant investments, announced on October 20, 2025, its plan to focus efforts on regaining a national exchange listing.

Nov 18, 2025, 1:37 PM

Aditxt Announces 1-for-113 Reverse Stock Split

ADTX

Delisting/Listing Issues

Proxy Vote Outcomes

Aditxt, Inc. (ADTX) announced a 1-for-113 reverse stock split, which became effective at 4:01 p.m. Eastern Time on October 31, 2025.
Trading on a split-adjusted basis will commence at the open of trading on November 3, 2025, on the Nasdaq Capital Market.
The primary purpose of the reverse stock split is to comply with Nasdaq's minimum bid price requirement.
Following the split, approximately 501,401 shares of common stock will be issued and outstanding, with any fractional shares being rounded up to the next whole share.

Oct 31, 2025, 8:30 PM

Aditxt, Inc. Issues Senior Unsecured Notes and Adjourns Annual Meeting for Reverse Stock Split Vote

ADTX

Debt Issuance

Proxy Vote Outcomes

Aditxt, Inc. issued senior unsecured notes with an aggregate original principal amount of $212,500 on September 12, 2025. These notes bear interest at a rate of 10% per annum and have a maturity date of September 30, 2025.
The company is required to use 100% of the gross proceeds from sales of common stock through at-the-market offerings or equity-line transactions to repay these notes.
The 2025 annual meeting of stockholders was adjourned from September 16, 2025, to September 23, 2025, to allow additional time for stockholders to vote.
Key proposals to be voted on at the adjourned meeting include the election of five (5) members to the board of directors, the ratification of dbb mckennon as the independent auditor, and granting discretionary authority for a reverse stock split at a ratio between 1-for-5 and 1-for-250.

Sep 16, 2025, 8:34 PM

Aditxt and Evofem Sign Sixth Merger Agreement Amendment

ADTX

M&A

Convertible Preferred Issuance

Aditxt, Inc. and Evofem Biosciences, Inc. entered into the sixth amendment to their Amended and Restated Merger Agreement on August 26, 2025.
This amendment updates the definition of "Unconverted Company Preferred Stock" to include Evofem's Series G-1 Preferred Stock.
It also clarifies that Evofem will assist in obtaining Exchange Agreements for convertible noteholders to exchange their notes for not more than 89,021 shares of Aditxt's preferred stock.
The amendment sets limits on dissenting shares, allowing for no more than 5,932,818 common shares or 202 preferred shares.
A new Series A-2 Convertible Preferred Stock of Aditxt, Inc., with a stated value of $1,000 per share, is introduced as part of the merger consideration.

Aug 27, 2025, 12:00 AM

Get instant answers from SEC filings, earnings calls & more